Therapeutic advances in eosinophilic granulomatosis with polyangiitis.
Curr Opin Rheumatol
; 34(3): 158-164, 2022 05 01.
Article
en En
| MEDLINE
| ID: mdl-35440531
ABSTRACT
PURPOSE OF REVIEW In recent years, therapeutic advances in eosinophilic granulomatosis with polyangiitis (EGPA) have changed our treatment paradigm. This review will summarize and discuss updates in management of EGPA, with a particular focus on biologic therapies. RECENT FINDINGS:
The anti-interleukin (IL)-5 agent mepolizumab (the first FDA-approved drug specifically for EGPA) is effective in induction and maintenance of remission particularly in patients with predominantly asthma and allergic manifestations, though efficacy in ANCA-positive, vasculitic disease is unclear; additional anti-IL-5 agents are under study. Rituximab is currently recommended for remission induction in severe disease, particularly in ANCA-positive patients with vasculitic manifestations, though the supportive evidence is mostly observational. Evidence supporting use of traditional DMARDs and other biologic agents such as omalizumab remains limited and observational.SUMMARY:
Although management of this heterogeneous disease remains challenging and unanswered questions remain, advances in biologics (particularly anti-IL-5 agents and an evolving interest in rituximab) have expanded our treatment armamentarium in EGPA.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Síndrome de Churg-Strauss
/
Granulomatosis con Poliangitis
Límite:
Humans
Idioma:
En
Revista:
Curr Opin Rheumatol
Asunto de la revista:
REUMATOLOGIA
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos